PL-8177

PL8177, a selective melanocortin-1 receptor agonist, achieved 33% clinical remission and 78% clinical response in ulcerative colitis patients compared to 0% and 33% for placebo, respectively, after eight weeks of treatment.

Palatin Technologies' Bremelanotide demonstrated positive results in a Phase IIb trial for Type 2 Diabetic Nephropathy, a leading cause of end-stage renal disease.

Palatin Technologies has completed enrollment in its Phase 2 study of oral PL8177 for ulcerative colitis, with topline data expected in Q1 2025.

Zealand Pharma reported positive Phase 1b results for petrelintide and dapiglutide, advancing both into Phase 2b trials for overweight and obese patients.

Palatin Technologies is focusing on obesity programs, including a Phase 2 study of BMT-801 with bremelanotide and tirzepatide, with topline results expected in Q1 2025.